Key Takeaway: Nurix is focused on developing innovative therapies for cancer and autoimmune diseases. The article mentions a first-in-human Phase 1a/b trial of NX-5948, a selective BTK degrader, but does not provide specific findings or results from the trial.
Price reaction · baseline $12.36 (2024-04-26 close) · clean, no other NRIX news in the window
day 0 close
+0.9%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.